CJC-1295 + Ipamorelin

Description

CJC-1295 + Ipamorelin — Dual-Pathway GH Secretagogue Blend

This research blend combines two complementary growth hormone secretagogues in a single vial: CJC-1295 (no DAC), a GHRH analog that acts on the pituitary somatotroph, and Ipamorelin, a selective ghrelin-receptor agonist. The pairing engages both pathways that govern natural GH pulse amplitude, which is why dual-agonist blends dominate preclinical research on endogenous GH release.

Mechanism of Action

CJC-1295 binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs and triggers Gs-protein–mediated cAMP elevation, driving GH synthesis and release. Ipamorelin, a pentapeptide GHRP, binds the growth hormone secretagogue receptor (GHS-R1a), activating phospholipase C and intracellular calcium signaling. Co-administration produces a synergistic GH pulse that exceeds either compound alone in animal models, while Ipamorelin’s receptor selectivity avoids meaningful prolactin, cortisol, or ACTH elevation — a key reason it is studied alongside CJC-1295 rather than older, less-selective GHRPs.

Research Applications

• Endogenous GH pulse and IGF-1 axis studies
• GHRH/GHS-R synergy research
• Lean mass preservation and somatic adaptation models
• Sleep architecture and slow-wave sleep investigations
• Recovery and musculoskeletal adaptation research
• Age-related somatopause modeling

Product Specifications

• Quantity: 5mg CJC-1295 (no DAC) + 5mg Ipamorelin per vial
• Purity: ≥99% each component (HPLC verified)
• Form: Lyophilized powder (co-formulated)
• Storage: Refrigerate after reconstitution
• Testing: Third-party lab tested, COA available on Portal
• Actual Tested Value: 11.26 mg

For research purposes only. Not for human or veterinary use.